“showed a trend”

Bacteria of the genus Coprococcus and family Ruminococcaceae showed a trend toward an increase in abundance following naproxen treatment ( P = 0.018, P = 0.022, FDR = 0.25, 0.25; Fig. 4A, B ).

NP VDR mRNA Downregulation in LDD Patients Similar to blood VDR, the analysis of NP VDR expression also showed a trend toward lower levels in the LDD group compared to controls ( p = 0.018).

CA4 showed a trend towards right hemispheric asymmetry ( r RH = 0.490, r LH = 0.312, difference = 0.178, Z = 2.36, p = 0.018, FDR‐ p = 0.055).

During negative emotion regulation, the decreased left SMA activation in the NSSI group showed a trend-level correlation with higher DERS scores ( r = −0.44, P = 0.018), which did not survive the Bonferroni-corrected threshold of P < 0.017.

The CDVAalso showed a trend of improvement at one month ( P = 0.018, Wilcoxon signed rank test) and three months postoperatively( P = 0.018, Wilcoxon signed rank test) when respectively compared to the preoperative value.

However, LSD post hoc comparisons showed a trend for mild deficits in SCA3 and SCA6 when compared to controls ( p = 0.018 and p = 0.041).

Comparison of the ECS match group (wish for ECS granted) and the mismatch group (preference for ECS, but not performed) showed a trend of higher PTSD symptoms postpartum in the mismatch group (IES is 7.7 in match group versus 10.83 in mismatch group ( p = 0.018 and 0.11 after post hoc Bonferroni tests)).

ALFF The ALFF of the left amygdala showed a trend interactive effect with group on the RT for anger ( F 3,60 = 3.58, p = 0.018), however, it did not survive the multiple comparison correction ( p FDR = 0.09).

In the AD high-risk cohort, metabolite ratios in the AD meta region PCr/ATP, and Pi/ATP showed significant inverse associations with FDG uptake (P < 0.01), while PME/PDE showed a trend toward association (P = 0.018) (see Table 3 and Fig. 2 ).

At one-factor analysis, 2-week regimens showed a trend toward a significantly higher efficacy than the 1-week regimens according to ITT criteria (OR: 1.44 with 95% CI of 1.10-2.84, P = 0.018), and were significantly effective at PP analysis (OR: 1.79 with 95% CI of 1.06%-3.03%, P = 0.029).

Compared to patients in Group 1, women over 65 showed a trend toward undertreatment across all risk categories, even if only in high-risk tumors did the difference reach statistical significance ( p = 0.018).

3B (i)], assessment of 4AD levels focusing on post-AI treatment showed a trend toward increased 4AD in patients who recurred when compared with patients who responded to AI therapy [ Fig. 3B (ii), t test P = 0.018, P adj . = 0.11].

The DRSP/EE monotherapy group showed a trend towards reduced GDM risk (χ 2 = 5.552, P = 0.018), but this difference did not reach statistical significance after Bonferroni correction.

Department of Defense 10.13039/100000005 PD220061 National Health and Medical Research Council 10.13039/501100000925 1195830 2008565 Group‐level comparisons showed a trend toward reduced functional connectivity between the left NBM and the VAN in PD‐VHs compared with PD‐NoVHs ( P = 0.018 uncorrected, Cohen's d = −0.661); however, this did not survive FDR correction ( P FDR = 0.060).

The PR group showed a trend of decreased frequency of CD4 + PD-1 + and CD8 + PD-1 + T cell subsets ( Figure 2(a) ) ( p =0.019, p =0.003).

Anxiety showed a trend towards improvement (SMD = −0.47; 95% CI −0.87 to −0.08; p –value = 0.019; 95% PI −1.60 to 0.66).

A McNemar test with a Bonferroni correction for multiple tests showed a trend toward the reduction of the proportion of patients with FSS score ≥4.5 after 1 ( p = 0.019) and 2 years ( p = 0.021) in comparison to baseline value.

Low expression levels of SYNE1, SULT1A1, and FAM76A were significantly associated with poor OS (HR = 0.6, 0.61, and 0.58, respectively; P < 0.002), while COL10A1 showed a trend toward good prognosis (HR = 1.25; P = 0.019) (Fig. 3 A).

Participants with MOH showed a trend toward higher PSQI global scores compared to those without MOH, which reached statistical significance only at Week 12 ( p = 0.019).

In Model 3 (adjusted for age, sex, and mGS), late log[CCL2] remained associated with change in ventricular volume and late log[IL-6] showed a trend (CCL2, β =33.41, 95% CI 7.22–59.60, p = 0.019; IL-6, β = 14.16, 95% CI −0.02–28.34, p = 0.050).

Achievement of CMR pre-HSCT showed a trend towards improved 2-year EFS (p=0.0198) but did not significantly change 2-year OS (p = 1).

Post hoc analysis demonstrated that favipiravir-treated patients showed a trend toward clinical improvement at day 7 among those with moderate COVID-19 (71.43% vs 55.86%, 95% CI: 0.0271 to 0.2843, P = 0.0199) and earlier resolution of fever and cough (p < 0.0001).

Moreover, patients with appropriate ICD therapy showed a trend toward lower right ventricular ejection fraction (RVEF) (development, P = 0.02; validation cohort, P = 0.22), with no significant differences in LV function and morphology (all P > 0.05).

This showed a trend toward poorer outcomes among patients with a tumor-only DDR alteration [PSA50: adjusted OR 0.29 (0.10-0.78), P = 0.02; PSA-PFS: adjusted HR 1.65 (0.95-2.87), P = 0.07; OS: adjusted HR 1.51 (0.73-3.10), P = 0.26].

FMI showed a trend of increase in both groups, reaching a significance at T12 only in patient of control group (7.1 ± 2 kg/m2 versus 8.0 ± 3.2 kg/m2; p = 0.02). 4.4.